Associate Director of Regulatory Project and Submission Management, Efi Sergi, delves into PRA’s experience creating an investigational new drug submission package for a COVID-19 treatment candidate and ways in which to optimize the submission preparation process.

Lessons Learned From Preparing and Submitting an IND Application for a COVID-19 Treatment Candidate

Explore related content and topics